Medivir’s Nomination Committee proposes new Board of Directors ahead of 2015 AGM

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced the Nomination
Committee’s proposal for a new Board of Directors that will be submitted to the
2015 Annual General Meeting. The 2014-2015 Nomination Committee comprises
representatives of the company’s three largest shareholders at the end of the
third quarter of 2014 who have accepted a seat on the Nomination Committee, and
the Chairman of the Board. The composition of the 2014-2015 Nomination Committee
was as follows:

  · Anders Algotsson, Chairman of the Nomination Committee, representing AFA
Försäkring
  · Maria Rengefors, representing Nordea Fonder
  · Birgitta Stymne Göransson, Chairman of the Board of Medivir AB
  · Bo Öberg, representing the class A shareholders

The Nomination Committee has agreed, ahead of the upcoming 2015 Annual General
Meeting, to propose that a new Board of Directors be appointed by means of the
re-election of the Board’s existing Members, namely Anna Malm Bernsten, Anders
Ekblom, Anders Hallberg, Bertil Samuelsson and Birgitta Stymne Göransson, and
the new election of two Members, namely Johan Harmenberg and Helena Levander.
The Committee also proposes the re-election of Birgitta Stymne Göransson as
Chairman of the Board.

Björn C. Andersson has declined re-election and Niklas Prager resigned his seat
on the Board in September 2014 in conjunction with his appointment as President
& CEO of the company.

Johan Harmenberg, born 1954, is a physician, Doctor of Medicine, and an
Associate Professor of Virology at the Karolinska Institute, and has conducted
scientific research work at MIT in Cambridge, Mass., USA. Johan is currently the
Chief Medical Officer of Glionova AB and Oncopeptides AB, and has previously
worked as a researcher, Chief Medical Officer, and Development Manager at,
amongst others, Roche, Astra, Pharmacia & Upjohn, Medivir and Algeta ASA. Johan
is also a former CEO of Axelar AB and Akinion AB and Member of the Boards of
Light-up AB and Oxypharma AB. He has published over 100 scientific papers and
abstracts, mainly on pharmaceuticals and the development of pharmaceuticals for
the treatment of cancer and infectious diseases.

Helena Levander, born 1957, gained a degree in Business Administration from the
Stockholm School of Economics. Helena is a founder and Chairman of the Board of
Nordic Investor Services AB and has extensive experience of corporate governance
issues. Helena has previously worked for companies such as Neonet, Odin
Förvaltning, Nordea Asset Management and SEB Asset Management. She is a Member
of the Boards of Concordia Maritime AB, Hans Andersson Recycling AB, NeuroVive
Pharmaceutical AB, Collector AB, Uniflex Bemanning AB and Stampen AB, and a
former Member of the Boards of a number of companies, including Gant AB,
Transatlantic AB, Nordisk Energiforvaltning ASA, Svensk Exportkredit AB (SEK),
Bure Equity AB, Mandator AB, Geveko AB, Erik Penser Bankaktiebolag and SBAB Bank
AB.

For further information, please contact:
Anders Algotsson, AFA Försäkring +46 (8) 696 40 67

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.